Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | 10% owner | April 08, 2025 | April 10, 2025 |
| NATHANS FAMOUS, INC.NATH · Entity 5644 | Director | August 19, 2024 | August 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date April 08, 2025 · Filed April 10, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 | IndirectR. Eide as managing partner for Pembroke | 984 |
Reported balance
After 2025-04-08 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2025-04-08 · Purchase · Acquired 492 · Balance 984 F2: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants. F5: N/A F3: Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power of up to 23% of the outstanding Common Stock based on their 984 shares of Preferred Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants. F4: Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2030-04-08 | IndirectR. Eide as managing partner for Pembroke | 3,358,364 |
Reported balance
After 2025-04-08 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2025-04-08 · Purchase · Acquired 1,679,182 · Balance 3,358,364 F2: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants. F4: Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power. |
| Common StockSEC Table I · non-derivative | Direct | 1,500 |
Reported balance
Holding disclosure · report date 2025-04-08 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 1,500 F1: Robert J. Eide is the direct holder of 750 shares of Common Stock, 0.0001 par value per share ("Common Stock") and the indirect holder of 750 shares of Common Stock as the managing member of Isagen LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Robert J. Eide is the direct holder of 750 shares of Common Stock, 0.0001 par value per share ("Common Stock") and the indirect holder of 750 shares of Common Stock as the managing member of Isagen LLC.
F2: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.
F3: Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power of up to 23% of the outstanding Common Stock based on their 984 shares of Preferred Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.
F4: Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power.
F5: N/A
NATHANS FAMOUS, INC.
Report date August 19, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.47 · Expires 2029-08-19 | Direct | 15,000 |
Reported balance
After 2024-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-19 · Grant · Acquired 15,000 · Balance 15,000 F1: The Options were granted to the Reporting Person pursuant to the Issuer's 2019 Stock Incentive Plan and will vest and become exercisable over a period of four years, with one-fourth (1/4) of such Options vesting on each of August 19, 2025, August 19, 2026, August 19, 2027 and August 19, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options were granted to the Reporting Person pursuant to the Issuer's 2019 Stock Incentive Plan and will vest and become exercisable over a period of four years, with one-fourth (1/4) of such Options vesting on each of August 19, 2025, August 19, 2026, August 19, 2027 and August 19, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2025 Filed Apr 10, 2025 13:59 UTC Amendment | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseWarrants · Derivative | 1,679,182 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0001477932-25-002583 · form4a.xml · derivative · entry 3 EIDE ROBERT J · CIK 0001181955 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · R. Eide as managing partner for Pembroke Disclosed balance after: 3,358,364 Underlying: Common Stock · 1,679,182 shares Expires 2030-04-08 F2 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants. F4 · ownership.nature: Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 13:59 UTC Amendment | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries C Convertible Preferred Stock · Derivative | 492 | $1,000.00 Strike: $0.59 | $492,000.00 |
DisclosureSEC source: 0001477932-25-002583 · form4a.xml · derivative · entry 2 EIDE ROBERT J · CIK 0001181955 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · R. Eide as managing partner for Pembroke Disclosed balance after: 984 Underlying: Common Stock · 839,591 shares Expires not disclosed F2 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants. F5 · derivative.expiration_date: N/A F3 · balance_after: Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power of up to 23% of the outstanding Common Stock based on their 984 shares of Preferred Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants. F4 · ownership.nature: Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:37 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $74.47 | $0.00 |
DisclosureSEC source: 0001104659-24-091303 · tm2422155-1_4seq1.xml · derivative · entry 1 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $0.01 per share · 15,000 shares Expires 2029-08-19 F1 · derivative.exercise_date: The Options were granted to the Reporting Person pursuant to the Issuer's 2019 Stock Incentive Plan and will vest and become exercisable over a period of four years, with one-fourth (1/4) of such Options vesting on each of August 19, 2025, August 19, 2026, August 19, 2027 and August 19, 2028. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 1,803 | $70.00 | $126,210.00 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 8 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 138 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 701 | $69.75 | $48,894.75 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 7 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 1,941 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 200 | $69.65 | $13,930.00 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 6 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 2,642 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 100 | $69.56 | $6,956.00 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 5 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 2,842 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 1,000 | $69.55 | $69,550.00 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 4 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 2,942 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 582 | $69.50 | $40,449.00 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 3 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 3,942 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 976 | $70.00 | $68,320.20 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 2 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 4,524 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:16 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | SaleCommon Stock | 2,000 | $70.03 | $140,050.00 |
DisclosureSEC source: 0000921895-18-003125 · form408477002_11202018.xml · nonDerivative · entry 1 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Isagen, LLC Disclosed balance after: 5,500 F1 · ownership.nature: These shares are owned directly by Isagen, LLC, a limited liability company of which the Reporting Person is the sole member. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:52 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | Exercise / conversion2010 Stock Incentive Plan (Right to Buy) · Derivative | 4,030 | $0.00 Strike: $33.44 | $0.00 |
DisclosureSEC source: 0000921895-18-002586 · form408477002_09132018.xml · derivative · entry 3 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,030 shares Expires 2019-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options to purchase shares replaced options to purchase 3,788 shares at an exercise price of $35.576, in connection with the recent special cash dividend of the Issuer and pursuant to Article IV(e) of the Issuer's 2010 Stock Incentive Plan, under which the Compensation Committee has the authority to make appropriate provisions upon the Issuer's declaration of a special cash dividend. The original options vested 25% each on the first through fourth anniversaries of August 6, 2014, the grant date, and the new options will have the same vesting terms and expiration date as the original grant. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:52 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | Exercise / conversionCommon Stock | 4,030 | $33.44 | $134,755.14 |
DisclosureSEC source: 0000921895-18-002586 · form408477002_09132018.xml · nonDerivative · entry 1 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired through the exercise of stock options granted pursuant to the Issuer's 2010 Stock Incentive Plan. F2 · balance_after: Does not include 250,000 shares held by Lorber Alpha II LP, for which the Reporting Person is an officer and director of its general partner and a trustee of the controlling shareholders of such entity. Mr. Eide does not have a pecuniary interest in the shares held by Lorber Alpha II LP. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 22:31 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | Grant2010 Stock Incentive Plan (Right to Buy) · Derivative | 4,030 | $0.00 Strike: $33.44 | $0.00 |
DisclosureSEC source: 0000921895-18-000148 · form408477002eid_01122018.xml · derivative · entry 4 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,030 Underlying: Common Stock · 4,030 shares Expires 2019-08-05 F3 · kind: In connection with the recent special cash dividend of the Issuer, the Issuer's Compensation Committee approved the exchange of options to purchase 3,788 shares at an exercise price of $35.576 for options to purchase 4,030 shares at an exercise price of $33.438. Pursuant to Article IV(e) of the Issuer's 2010 Stock Incentive Plan, the Compensation Committee has the authority to make appropriate provisions upon the Issuer's declaration of a special cash dividend. The original options vested 25% each on the first through fourth anniversaries of August 6, 2014, the grant date, and the new options will have the same vesting terms and expiration date as the original grant. F3 · derivative.exercise_date: In connection with the recent special cash dividend of the Issuer, the Issuer's Compensation Committee approved the exchange of options to purchase 3,788 shares at an exercise price of $35.576 for options to purchase 4,030 shares at an exercise price of $33.438. Pursuant to Article IV(e) of the Issuer's 2010 Stock Incentive Plan, the Compensation Committee has the authority to make appropriate provisions upon the Issuer's declaration of a special cash dividend. The original options vested 25% each on the first through fourth anniversaries of August 6, 2014, the grant date, and the new options will have the same vesting terms and expiration date as the original grant. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 22:31 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | Disposition to issuer2010 Stock Incentive Plan (Right to Buy) · Derivative | 3,788 | $0.00 Strike: $35.58 | $0.00 |
DisclosureSEC source: 0000921895-18-000148 · form408477002eid_01122018.xml · derivative · entry 3 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,788 shares Expires 2019-08-05 F3 · kind: In connection with the recent special cash dividend of the Issuer, the Issuer's Compensation Committee approved the exchange of options to purchase 3,788 shares at an exercise price of $35.576 for options to purchase 4,030 shares at an exercise price of $33.438. Pursuant to Article IV(e) of the Issuer's 2010 Stock Incentive Plan, the Compensation Committee has the authority to make appropriate provisions upon the Issuer's declaration of a special cash dividend. The original options vested 25% each on the first through fourth anniversaries of August 6, 2014, the grant date, and the new options will have the same vesting terms and expiration date as the original grant. F3 · derivative.exercise_date: In connection with the recent special cash dividend of the Issuer, the Issuer's Compensation Committee approved the exchange of options to purchase 3,788 shares at an exercise price of $35.576 for options to purchase 4,030 shares at an exercise price of $33.438. Pursuant to Article IV(e) of the Issuer's 2010 Stock Incentive Plan, the Compensation Committee has the authority to make appropriate provisions upon the Issuer's declaration of a special cash dividend. The original options vested 25% each on the first through fourth anniversaries of August 6, 2014, the grant date, and the new options will have the same vesting terms and expiration date as the original grant. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 20:37 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | Exercise / conversion2010 Stock Incentive Plan (Right to Buy) · Derivative | 11,361 | $0.00 Strike: $35.58 | $0.00 |
DisclosureSEC source: 0000921895-17-002334 · form408477002_09202017.xml · derivative · entry 4 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,361 shares Expires 2019-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options to purchase shares replaced options to purchase 10,000 shares at an exercise price of $53.89, in connection with a special cash dividend of the Issuer,and pursuant to Article IV(e) of the Issuer's 2010 Stock Incentive Plan, under which the Issuer's Compensation Committee has the authority to make appropriate provisions upon the Issuer's declaration of a special cash dividend. The original options vested in four equal installments beginning on August 6, 2015, and these replacement options have the same vesting terms and expiration date as the original grant. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 20:37 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | Tax withholdingCommon Stock | 5,862 | $68.95 | $404,184.90 |
DisclosureSEC source: 0000921895-17-002334 · form408477002_09202017.xml · nonDerivative · entry 2 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,611 F3 · shares: Transaction represents withholding of shares based on net exercise to satisfy exercise cost. F2 · balance_after: Does not include 250,000 shares held by Lorber Alpha II LP, for which the Reporting Person is an officer and director of its general partner and a trustee of the controlling shareholders of such entity. Mr. Eide does not have a pecuniary interest in the shares held by Lorber Alpha II LP. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 20:37 UTC | NATHANS FAMOUS, INC. NATH · Entity 5644 | Exercise / conversionCommon Stock | 11,361 | $35.58 | $404,178.94 |
DisclosureSEC source: 0000921895-17-002334 · form408477002_09202017.xml · nonDerivative · entry 1 EIDE ROBERT J · CIK 0001181955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired through the exercise of stock options granted on August 6, 2014 pursuant to the Issuer's 2010 Stock Incentive Plan. F2 · balance_after: Does not include 250,000 shares held by Lorber Alpha II LP, for which the Reporting Person is an officer and director of its general partner and a trustee of the controlling shareholders of such entity. Mr. Eide does not have a pecuniary interest in the shares held by Lorber Alpha II LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.